Latest news with #Cigna
Yahoo
6 hours ago
- Health
- Yahoo
Premier Primary Care to Celebrate Grand Opening in Urbana, MD with Ribbon Cutting and Community Open House
URBANA, Md., June 6, 2025 /PRNewswire/ -- Premier Primary Care is proud to announce the official grand opening of its new medical office at 3546 Worthington Blvd Suite #3 in Urbana, Maryland. The new practice will celebrate this exciting milestone with a ribbon cutting ceremony in partnership with the Frederick County Chamber of Commerce on Thursday, June 12 at 12:00 PM. The ceremony will be followed by an open house featuring complimentary food, refreshments, business card raffle and Rita's Italian Ice. Premier Primary Care is thrilled to open its doors in Urbana and provide high-quality, personalized healthcare to individuals and families throughout the Frederick County community. The practice is now accepting new patients and offers a full spectrum of primary care services tailored to adult patients. "Our goal is to create a welcoming, patient-focused environment where individuals and families can receive the comprehensive care and personal service they deserve," said Dr Sassan Taghizadeh, one of the four doctors at Premier Primary Care. "We're honored to be part of the Urbana community and look forward to making a positive impact on the health and well-being of our new neighbors." The practice specializes in preventive care, routine check-ups, chronic condition management, and individualized health screenings for conditions such as diabetes, hypertension, and cancer. Additional services include physicals, lab testing, and post-diagnosis care, all designed to support long-term health and wellness. Located at 3546 Worthington Blvd, Suite 301, Urbana, MD 21704, Premier Primary Care offers elevator access and ample parking for patient convenience. The practice is currently accepting most major insurance plans, including Blue Cross Blue Shield, Cigna, Aetna, and Medicare. The entire community is invited to attend the grand opening celebration, meet our care team, and tour our new office space. For more information or to schedule an appointment, please visit or call (301) 979-9772. View original content: SOURCE Premier Primary Care Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
2 days ago
- Health
- CBS News
Allegheny Health Network warns most Signa customers could lose in-network coverage unless agreement is reached
Allegheny Health Network is warning that most Cigna members won't have in-network access to its physicians and facilities unless a new agreement can be reached by the end of the month. In a letter sent to patients, Allegheny Health Networks said it has been "unable to reach a fair and mutually acceptable agreement" with Cigna after several months of negotiation. "We understand how disconcerting and stressful this news may be for you, and please know that it is our sincerest hope that we will reach a new agreement with Cigna before June 30 that will enable you to continue receiving the health care services you need at AHN over the long term," AHN's letter read. If the contract does end, the health system said it's "committed" to making sure there are no care disruptions for Cigna members who are actively in treatment. AHN also said it will try to ensure that transitions to new physicians, if necessary, are "seamless." "In the unfortunate event that AHN's contract with Cigna does come to an end, however, our highest priority will be minimizing the inconvenience, stress, and burden of this development on you and other Cigna members," the letter says. AHN encourages anyone with questions to contact the Cigna customer service line on the back of their card or call 1-800-997-1654. In 2023, about 20,000 Cigna customers were at risk of losing in-network coverage at Allegheny Health Network facilities, but the two did reach an agreement.
Yahoo
2 days ago
- Business
- Yahoo
Cigna, Allegheny Health Network contract dispute threatens in-network access for thousands
Thousands of Cigna commercially insured people in the Pittsburgh region could lose in-network access to Allegheny Health Network by the end of June in a dispute over a new contract. AHN patients who use Cigna were notified this week of the impasse in negotiations on a new contract, meaning most care would be out of network if there isn't a new contract in place by June 30, according to a copy of a letter obtained by the Pittsburgh Business Times. About 20,000 Cigna members have used an AHN provider within the past year. It's the second such dispute in the past two years. The contract that runs out is for commercially insured members and not for Medicare or Medicare Advantage members. Cigna in March 2025 sold the Medicare-related business to Health Care Service Corp., a Chicago-based insurer. HCSC's coverage of Medicare and Medicare Advantage patients isn't impacted by this dispute and those patients will continue to have in-network access to AHN no matter what happens to the commercial insurance agreement. Click here to read more from our partners at the Pittsburgh Business Times. Download the FREE WPXI News app for breaking news alerts. Follow Channel 11 News on Facebook and Twitter. | Watch WPXI NOW
Yahoo
30-05-2025
- Business
- Yahoo
The Cigna Group (CI): A Bull Case Theory
We came across a bullish thesis on The Cigna Group (CI) on Antonio Linares' Substack. In this article, we will summarize the bulls' thesis on CI. The Cigna Group (CI)'s share was trading at $312.68 as of 22nd May. CI's trailing and forward P/E were 17.43 and 10.65 respectively according to Yahoo Finance. adriaticfoto/ Cigna's new deal with Eli Lilly and Novo Nordisk to offer capped prices for GLP-1 weight loss drugs may seem disruptive at first glance, particularly to players like Hims, but it reinforces the structural dynamics that benefit the company. As the fourth-largest pharmacy benefit manager (PBM) in the U.S., Cigna's concession reflects the intense competition between Lilly and Novo to scale their relatively undifferentiated GLP-1 offerings. While this specific deal may cap prices for GLP-1s, PBMs will likely offset this by inflating prices elsewhere, consistent with their broader business model that thrives on the complexity and pricing inefficiencies of the U.S. healthcare system. For Hims, which isn't fundamentally a GLP-1 business but rather a vertically integrated healthcare platform, the overall inflationary environment driven by PBMs enhances its value proposition—offering lower-cost, high-efficiency solutions below copay. Hims has guided for $750 million in 2025 weight loss revenue, largely from oral alternatives and generic liraglutide, both significantly cheaper than branded injectables like Wegovy. Hims's platform, which continues to evolve with personalized care and efficiency gains, is uniquely positioned to address a broad array of health needs in a way that is difficult for traditional PBM-centered models to replicate. The company's partnership with Novo and potential future deal with Lilly would further de-risk its growth. With a recent acquisition of a peptide manufacturing facility and a pipeline far beyond GLP-1s, Hims is building a scalable, cost-effective precision medicine platform. As the market remains fixated on GLP-1 narratives, Hims quietly compounds free cash flow and strategic value, offering investors an increasingly attractive long-term opportunity. We have previously covered The Cigna Group (CI) in January 2025 wherein we summarized a bull thesis by Tsachy Mishal on twitter. Mishal named Cigna (CI) a top pick, citing its stable model and low valuation. Since then, the company has completed a $3.7B asset sale and is on track to repurchase up to 12% of its shares. With political risk around PBMs easing and strong buyback execution, Cigna remains undervalued and well-positioned for continued upside. As of May 2025, the stock has risen by 13.23%. The Cigna Group (CI) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 72 hedge fund portfolios held CI at the end of the fourth quarter which was 66 in the previous quarter. While we acknowledge the risk and potential of CI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CI but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-05-2025
- Business
- Yahoo
The Cigna Group (CI): A Bull Case Theory
We came across a bullish thesis on The Cigna Group (CI) on Antonio Linares' Substack. In this article, we will summarize the bulls' thesis on CI. The Cigna Group (CI)'s share was trading at $312.68 as of 22nd May. CI's trailing and forward P/E were 17.43 and 10.65 respectively according to Yahoo Finance. adriaticfoto/ Cigna's new deal with Eli Lilly and Novo Nordisk to offer capped prices for GLP-1 weight loss drugs may seem disruptive at first glance, particularly to players like Hims, but it reinforces the structural dynamics that benefit the company. As the fourth-largest pharmacy benefit manager (PBM) in the U.S., Cigna's concession reflects the intense competition between Lilly and Novo to scale their relatively undifferentiated GLP-1 offerings. While this specific deal may cap prices for GLP-1s, PBMs will likely offset this by inflating prices elsewhere, consistent with their broader business model that thrives on the complexity and pricing inefficiencies of the U.S. healthcare system. For Hims, which isn't fundamentally a GLP-1 business but rather a vertically integrated healthcare platform, the overall inflationary environment driven by PBMs enhances its value proposition—offering lower-cost, high-efficiency solutions below copay. Hims has guided for $750 million in 2025 weight loss revenue, largely from oral alternatives and generic liraglutide, both significantly cheaper than branded injectables like Wegovy. Hims's platform, which continues to evolve with personalized care and efficiency gains, is uniquely positioned to address a broad array of health needs in a way that is difficult for traditional PBM-centered models to replicate. The company's partnership with Novo and potential future deal with Lilly would further de-risk its growth. With a recent acquisition of a peptide manufacturing facility and a pipeline far beyond GLP-1s, Hims is building a scalable, cost-effective precision medicine platform. As the market remains fixated on GLP-1 narratives, Hims quietly compounds free cash flow and strategic value, offering investors an increasingly attractive long-term opportunity. We have previously covered The Cigna Group (CI) in January 2025 wherein we summarized a bull thesis by Tsachy Mishal on twitter. Mishal named Cigna (CI) a top pick, citing its stable model and low valuation. Since then, the company has completed a $3.7B asset sale and is on track to repurchase up to 12% of its shares. With political risk around PBMs easing and strong buyback execution, Cigna remains undervalued and well-positioned for continued upside. As of May 2025, the stock has risen by 13.23%. The Cigna Group (CI) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 72 hedge fund portfolios held CI at the end of the fourth quarter which was 66 in the previous quarter. While we acknowledge the risk and potential of CI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CI but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
